


---

# Contents

---



<b>Preface</b> .....	vii
<b>Contributors</b> .....	ix
<b>Part 1 Molecular biology of chronic myeloid leukaemia</b>	
1. BCR/ABL gene structure and BCR function <i>Nora Heisterkamp, John Groffen</i> .....	3
2. BCR/ABL protein domain function and signaling <i>Ann Marie Pendergast</i> .....	19
3. Abnormalities in hematopoietic progenitor adhesion <i>Ravi Bhatia, Catherine Verfaillie</i> .....	41
4. Functional complementation of cytokine receptor signaling by BCR/ABL <i>Eugene Y Koh, George Q Daley</i> .....	55
5. Progenitor cell dynamics <i>Connie J Eaves, Allen C Eaves</i> .....	73
6. Animal models of Philadelphia-positive leukemia <i>Richard A Van Etten</i> .....	101
<b>Part 2 Conventional treatment for chronic myeloid leukaemia</b>	
7. Biology of interferon <i>Thomas Fischer, Moshe Talpaz</i> .....	135
8. Interferon- $\alpha$ dosage regimens <i>Patricia CA Shepherd</i> .....	149
9. Chemotherapy versus interferon: Long-term effects <i>Andreas Hochhaus, Rüdiger Hehlmann</i> .....	165
10. Chemotherapy <i>Bengt Simonsson</i> .....	181
11. Interferon- $\alpha$ and Ara-C <i>Gianantonio Rosti, Elena Trabacchi, Francesca Bonifazi, Antonio de Vivo, Simona Bassi, Sante Tura</i> .....	191
12. Prognostic factors <i>Joerg Hasford, Markus Pfirrmann, Rüdiger Hehlmann, Patricia CA Shepherd, François Guilhot, François X Mahon, Josef Thaler, Juan L Steegmann, Hanneke C Kluin-Nelemans, Andries Louwagie, Kazunori Ohnishi, Otto Kloke</i> .....	205
13. Evidence-based guidelines for the treatment of chronic-phase chronic myeloid leukemia <i>Richard T Silver</i> .....	225
<b>Part 3 Allogeneic haematopoietic stem cell transplantation for chronic myeloid leukaemia</b>	
14. Donor selection in allogeneic bone marrow transplantation <i>Andrea L Pay, Ann-Margaret Little, J Alejandro Madrigal</i> .....	241
15. Risk assessment for allogeneic transplantation <i>Alois Gratwohl</i> .....	251
16. The decision whether to allograft a patient with CML <i>John M Goldman</i> .....	263

17.	Conditioning regimens and T-cell depletion	<i>Charles Craddock</i>	273
18.	Blood versus marrow stem cells	<i>Peter Dreger, Norbert Schmitz</i>	287
19.	HLA-identical sibling transplantation	<i>David G Savage</i>	303
20.	Results with alternative donors	<i>Jane F Apperley</i>	323
21.	Patient monitoring after allogeneic stem cell transplantation or interferon- $\alpha$ therapy	<i>Andreas Hochhaus</i>	339
22.	Recommendations for assessment and definitions of response and relapse in CML: A report from the Chronic Leukemia Working Committee of the IBMTR	<i>Sergio A Giralto, John M Goldman, Claudio Anasetti, Francisco Cervantes, Richard Champlin, Nicholas Cross, Andreas Hochhaus, John P Klein, Esperanza Papadopoulos, Kathleen Sobocinski, Daniel Weisdorf, Mary Horowitz on behalf of the Chronic Leukemia Working Committee of the IBMTR</i>	357
23.	Basis of GVL	<i>John M Barrett</i>	369
24.	Donor lymphocyte infusions	<i>Francesco Dazzi, Hans J Stauss</i>	385
25.	Late complications, including late relapse	<i>Gérard Socié, Rochelle E Curtis, John P Klein</i>	401
<b>Part 4 Autografting in chronic myeloid leukaemia</b>			
26.	Autografting with unmanipulated stem cells: The European experience	<i>Arnaud Pigneux, Eduardo Olavarria, François X Mahon, Josy Reiffers</i>	421
27.	Autografting with cultured marrow	<i>Michael J Barnett, Connie J Eaves, Allen C Eaves</i>	431
28.	Autografting with Ph-negative haematopoietic progenitor cells	<i>Angelo M Carella</i>	445
29.	Autologous hematopoietic stem cell transplantation: Experience at the University of Minnesota	<i>Philip McGlave</i>	457
30.	What role for autografting? A personal view	<i>Stephen G O'Brien</i>	465
<b>Part 5 Target-directed therapies: Chronic myeloid leukaemia as a paradigm for oncology</b>			
31.	Gene therapy	<i>Alan M Gewirtz</i>	475
32.	Target-directed therapies	<i>Mikhail L Gishizky</i>	485
33.	Development of kinase inhibitors	<i>Enrica Lerma, Toa Wang, Takuma Fujii, Victor Chang, David Austin, Albert A Deisseroth</i>	495
34.	STI571 as a therapeutic agent	<i>Michael E O'Dwyer, Michael J Mauro, Brian J Druker</i>	501
35.	Immunotherapeutic strategies	<i>Kathleen NS Cathcart, Javier Pinilla, David A Scheinberg</i>	507
	<b>Index</b>		521